Bentsu Ro

Array ( [id] => 19949457 [patent_doc_number] => 12320817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Enzyme-linked immunosorbent assay (ELISA) method and monoclonal antibody for giant panda relaxin-3 (RLN3) [patent_app_type] => utility [patent_app_number] => 18/808126 [patent_app_country] => US [patent_app_date] => 2024-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 2865 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18808126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111270 [patent_doc_number] => 20240123020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/395108 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281587 [patent_doc_number] => 20240218061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/390085 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20413055 [patent_doc_number] => 12496317 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Compositions and methods for repairing cartilage defects [patent_app_type] => utility [patent_app_number] => 18/509397 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10628 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232200 [patent_doc_number] => 20240189391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 18/509798 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19608910 [patent_doc_number] => 12157776 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => Anti-PAPP-A antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/508874 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 21812 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462498 [patent_doc_number] => 20240316167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => TREATMENT OF URTICARIA [patent_app_type] => utility [patent_app_number] => 18/505699 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448933 [patent_doc_number] => 20240309063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => TGF- B receptor II isoform, fusion peptide, methods of treatment and methods in vitro [patent_app_type] => utility [patent_app_number] => 18/502333 [patent_app_country] => US [patent_app_date] => 2023-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556469 [patent_doc_number] => 20240368261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION [patent_app_type] => utility [patent_app_number] => 18/488265 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097830 [patent_doc_number] => 20240117058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/485116 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170939 [patent_doc_number] => 20240156913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => TREATMENT AND PREVENTION OF METABOLIC DISEASES [patent_app_type] => utility [patent_app_number] => 18/482399 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817507 [patent_doc_number] => 20230391847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => PROCESSES FOR MAKING AND USING A CELLULAR FIBRONECTIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/448294 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902764 [patent_doc_number] => 20240018249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 18/366770 [patent_app_country] => US [patent_app_date] => 2023-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18366770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808653 [patent_doc_number] => 20230382987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER [patent_app_type] => utility [patent_app_number] => 18/364173 [patent_app_country] => US [patent_app_date] => 2023-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754013 [patent_doc_number] => 20230357377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST [patent_app_type] => utility [patent_app_number] => 18/339147 [patent_app_country] => US [patent_app_date] => 2023-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18339147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187821 [patent_doc_number] => 20240166734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => ANTI-GDF-15 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/336713 [patent_app_country] => US [patent_app_date] => 2023-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18336713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265376 [patent_doc_number] => 20240209075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization [patent_app_type] => utility [patent_app_number] => 18/333425 [patent_app_country] => US [patent_app_date] => 2023-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18333425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172483 [patent_doc_number] => 20240158457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => INTERLEUKIN-18 RECEPTOR BINDING POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/319903 [patent_app_country] => US [patent_app_date] => 2023-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18319903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793352 [patent_doc_number] => 12234282 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors [patent_app_type] => utility [patent_app_number] => 18/318336 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 27 [patent_no_of_words] => 14612 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18598422 [patent_doc_number] => 20230273221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION [patent_app_type] => utility [patent_app_number] => 18/312879 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312879 [rel_patent_id] =>[rel_patent_doc_number] =>)